Funds Benchmark is now on iPhoneGet the iPhone app Research and compare funds on the go.
Scan to install Scan to download Funds Benchmark on the App Store Download on the App StoreApp Store
← Back to Explore

Biotechnology

Funds with exposure to this sector
+15.0%

£31.3B of assets in Biotechnology · 6 sub-categories · average OCF 1.00%.

How funds with Biotechnology exposure have returned on average.

Average 1Y return to October 2026 end, GBP net total return.

The headline is the average return of the funds, to October 2026 end. The chart follows the ten funds with most exposure, equal weighted, weekly points built from daily prices, to 30 Oct 2026. They measure different things, so the numbers differ.

Source: FE fundinfo. Past performance is not a reliable guide to future returns.

Composite of the 10 most exposed funds with 1Y of history, equal weight, GBP total return, NAV to 30 Oct 2026. 10 funds.

Funds in this line

The funds used in the chart above.

Funds
78
Monthly universe, as at October 2026.
Assets in Biotechnology (GBP)
£31.3B
Average portfolio share
25.8%
Weekly snapshot to 30 Oct 2026, among funds with this exposure.
Average ongoing charge
1.00%

Biotechnology exposure on Funds Benchmark gathers the funds that hold Biotechnology companies, with an average 1 year return of +15.0% to October 2026 and an average ongoing charge of 1.00%. North America, Europe ex UK and Greater China lead the region breakdown among them. Open any fund for its holdings, performance and allocation breakdown, or select a region below to filter the funds shown. Fund data is from FE fundinfo. Past performance is not a reliable guide to future returns.

Regional mix

What Biotechnology exposure is made of.
45.6%
North America
  • North America45.6%
  • Europe ex UK32.3%
  • Greater China6.0%
  • Others16.1%
North America is the largest at 45.6%. Mapped to a region: 98% of country exposure. Shares add up to 100% across the nine regions.

Regions inside this sector

Pick one to filter the funds and holdings below.
North America 41 funds · 36.9% average portfolio share across Biotechnology funds +20.5% ▲ Average 1Y return
Asia Pacific ex Japan and China 16 funds · 2.9% average portfolio share across Biotechnology funds +15.2% ▲ Average 1Y return Fewer than 5 funds with enough history
United Kingdom 29 funds · 4.6% average portfolio share across Biotechnology funds +14.8% ▲ Average 1Y return Fewer than 5 funds with enough history
Japan 22 funds · 4.5% average portfolio share across Biotechnology funds +14.7% ▲ Average 1Y return Fewer than 5 funds with enough history
Europe ex UK 49 funds · 26.2% average portfolio share across Biotechnology funds +14.7% ▲ Average 1Y return
Greater China 19 funds · 4.8% average portfolio share across Biotechnology funds +14.6% ▲ Average 1Y return Fewer than 5 funds with enough history

Fund counts here are a separate set from the Funds figure above.

Dots: last Friday of each month, GBP total return, ten most exposed funds with the sub-category at 10% or more (at least five funds), equal weighted, against the whole category (small grey dots). Bars: average portfolio share, relative to the largest.

Largest Biotechnology funds

The biggest funds with this exposure, to open or compare.
All funds Compare the first 3
See all fundsA free account shows the full list.

Top Biotechnology funds by assets under management, one share class per fund.

Biotechnology holdings

Positions that appear most often among the ten largest holdings of these funds.
1 AMGEN INC. 4.2%
2 GILEAD SCIENCES, INC. 4.4%
3 ELI LILLY AND COMPANY 10.6%
See all holdingsA free account shows the full list.

Positions that appear most often among the ten largest holdings of the funds we list. Bar = average weight among the funds that have the position in their ten largest holdings.

All funds with Biotechnology exposure

Largest by size first, one share class per fund. Open any fund for its holdings, performance and allocation breakdown.